in 25/31. Two patients developed an EEG pattern resembling electrical status epilepticus during sleep. Ataxia was observed in 7/34 cases. We describe 7 truncating and 18 missense variants, including 4 recurrent variants (Gly232Val, Ala288Val, Val342Met, and Gly362Arg). Significance: Most patients carrying pathogenic SLC6A1 variants have an MAE phenotype with language delay and mild/moderate ID before epilepsy onset. However, ID alone or associated with focal epilepsy can also be observed.
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| INTRODUCTION
The voltage-dependent c-aminobutyric acid (GABA) transporter 1 (GAT-1), encoded by SLC6A1, is one of the major GABA transporters of the human central nervous system. 1 GAT-1 is expressed primarily in the nerve terminals of GABAergic interneurons but can also be found in astrocytes, and has been shown to be crucial for the reuptake of GABA from the synapses and for its clearing from the extracellular space. 2 In addition to the neocortex, GAT-1 is found in abundance in the cerebellum. 3 GAT-1 knockout mice exhibit spontaneous spike-wave discharges (SWDs) and absence seizures. 4 In 2014, Dikow et al., 5 described 3 patients with intellectual disability (ID), epilepsy/electroencephalography (EEG) abnormalities, ataxia and stereotypic hand movements, and a microdeletion at 3p25.3, including the 2 GABA transporter genes, SLC6A1 and SLC6A11. Recently, de novo SLC6A1 variants discovered by large exome sequencing studies were reported in 3 patients with ID, myoclonic atonic (MA) seizures, delayed speech and delayed walking, autism spectrum disorders, and absence seizures, as well as in a patient with epileptic encephalopathy. [6] [7] [8] In 2015, we reported de novo inactivating variants in SLC6A1 in up to 4% of patients with myoclonic atonic epilepsy (MAE), suggesting that pathogenic SLC6A1 variants might be specific for MAE. 9 MAE is a syndrome characterized by the presence of myoclonic-atonic seizures, usually in an otherwise normal child, which may typically develop cognitive impairment after seizure onset (reviewed in Guerrini and Aicardi). 10 Extensive searches in other epileptic encephalopathy cohorts, such as epileptic spasms or Lennox-Gastaut syndrome, failed to detect pathogenic variants in this gene.
Here we aim to better characterize the clinical presentation and electroencephalographic features associated with pathogenic SLC6A1 variants.
| MATERIAL AND METHODS
Patients with presumed pathogenic variants in SLC6A1 were collected through an international collaboration between epilepsy genetics centers worldwide. The cohorts included for screening consisted primarily of patients with ID or childhood epilepsies including childhood encephalopathies, without a previously identified genetic cause. Probands and families, when available, underwent clinical, neurophysiological, and genetic examinations. All the available EEG data were collected and reviewed by a single epileptologist (EG). Seizures were classified according to the International League Against Epilepsy (ILAE) classification. 11 Atypical absences were defined as absence seizures with additional clinical features (eg, myoclonic jerks) and with an EEG pattern of diffuse spike-wave <3 c/s with a slower onset and offset compared to typical absence seizures. 12 Cognitive development was based mainly on the assessment of the psychomotor development by the referring physicians; only in a few cases was a formal neuropsychological testing performed. For the diagnosis of MAE, we adopted the following diagnostic criteria: (1) usually normal development before epilepsy onset and absence of brain structural abnormali-ties; (2) onset of myoclonic, myoclonic-atonic, or atonic seizures between 7 months and 6 years of age; (3) EEG: 2-3 Hz generalized spike/polyspikes-and-slow waves; (4) diagnoses of benign myoclonic epilepsy of infancy (BMEI), severe myoclonic epilepsy of infancy (SMEI), and Lennox-Gastaut syndrome (LGS) have been excluded. (https://www.epilepsydiagnosis.org/syndrome/epilepsy-myo clonic-atonic-overview.html).
All probands and/or their parents or legal guardians signed an informed consent form. The study was approved by the local ethics committees.
Variants were classified as pathogenic if they were (1) nonsynonymous, splice-site altering, or truncating changes; (2) (4) were either de novo changes, inherited from an unaffected mosaic parent, or inherited from an affected parent. We used Sanger sequencing to confirm all variants and to perform segregation analysis.
| RESULTS
We identified 30 unpublished patients with a pathogenic SCL6A1 variant (24 probands and 6 affected family members). Moreover, we included additional clinical information of 4 previously published cases. One (Patient 25) had only briefly been described previously and the 3 remaining cases were included for electroencephalographic characterization (Patients 5, 28, and 34) ( Table 1 ). In total, we studied 34 SLC6A1-positive patients. Gender ratio was 19 female to 15 male patients.
| Genetics
We report on a cohort of 24 previously unpublished probands with pathogenic SLC6A1 variants. Twenty variants occurred de novo in the affected proband, and 2 variants segregated in a dominant manner with the phenotype in the affected family ( Figure 1 ). In 2/24 probands (Patients 12 and 24), segregation analysis could not be performed, and the inheritance mode remained unclear. However, both probands had missense variants identical to those found in other affected probands in this study. We found 18 missense variants, 2 splice-site variants, 1 frameshift variant, 3 nonsense variants, and 1 in-frame deletion. The 18 missense variants all affect highly conserved nucleotides and are absent from control databases (Figure 2) . Overall, the variants suggest that loss of function of GAT-1 is the likely disease mechanism, as reported previously. All subjects but 1 (Patient 17) had cognitive impairment at the time of the inclusion in the study.
| Cognitive development
Sixteen of 34 patients had mild ID, 12 had moderate ID, 3 had severe ID, and 2 had learning disabilities. The most common feature was language delay, described in 16/ 34, whereas 4 probands presented mainly nonverbal deficits (Patients 1, 25, 27, and 29). There was no apparent correlation between seizure control and cognitive profile.
A large proportion of the 34 SLC6A1 mutation carriers had behavioral problems, such as aggressive behavior 
| Epilepsy phenotype
Thirty-one of 34 individuals had epilepsy, namely 27 of 28 probands (27 unpublished and 4 previously published cases) and 4 of 6 family members. Mean age at seizure onset was 3.7 years (range 0.5-7 years); 2 probands had epilepsy onset before the age of 1 year. Mean age at follow-up was 11.3 years (range 2-21 years).
Affected individuals presented with a variety of seizure types: absences not further specified (14/31), atypical absences (10/31), atonic seizures (14/31), and myoclonic or myoclonic-atonic seizures (12/31) were the most common. A few subjects (5/31) also had generalized tonic-clonic seizures (GTCS) ( Table 1) . At the time of diagnosis, epilepsy syndromes were described as MAE in 16 patients and LGS in 1 patient (Patient 25), early onset absence epilepsy (EOAE) in its atypical form (Patient 1), eyelid myoclonia with absences (Patient 22), and childhood absence epilepsy (CAE) (Patients 17 and 33) . Seven further patients presented with a generalized epilepsy difficult to classify because of inconsistencies of the electroclinical picture such as absence seizures (up to 100/day), atypical EEG pattern, or because further clinical details and EEG data were not available. Finally, 3 patients were diagnosed with focal epilepsy: 1 had temporal lobe epilepsy (Patient 24) and the other 2 had atypical childhood epilepsy with centrotemporal spikes (aBECTS) (Patients 6 and 28). The diagnosis of aBECTS was based on the description of focal motor seizures during sleep and on the presence of centrotemporal spikes on EEG, together with several atypical features (ID with autistic features or mild neurological deficits, the epilepsy history, and the topography of the EEG abnormalities).
Twenty of 31 patients with epilepsy became seizurefree. Ten of them were treated with valproic acid (VPA), either as monotherapy or in combination with clonazepam (CLZ), lamotrigine (LTG), or levetiracetam (LEV). The remaining 10 subjects became seizure-free on LTG, ethosuximide (ESM), LEV, and LTG or CLZ, alone or in combination. Five further patients were treated with VPA, all achieving partial seizure control. Vagus nerve stimulation (VNS) was attempted in 1 patient with LGS (Patient 25) without benefit. None of the patients reported herein has tried a ketogenic diet, recently described as potentially effective for MAE.
| Neurophysiological and imaging characteristics
EEG data were available in 27/34 SLC6A1-positive patients, all with epilepsy (23 novel cases and 4 previously published), and were abnormal in all cases. A slowing of the background activity was observed in 11/28 subjects and bursts of irregular generalized 2.5-3.5 Hz spikes/polyspikes and slow waves with a gradual onset in the occipital regions were present in 25/28 patients ( Figure 3) . In some instances, these epileptic discharges correlated with staring and loss of consciousness with or without a myoclonic or atonic component, in different combinations, resulting in atypical absences, myoclonic-atonic seizures, atonic seizures/drop attacks, or myoclonic seizures. Two further probands had focal epileptiform abnormalities in the centrotemporal during the hyperpnea). Of interest, in Patient 12, epilepsy evolved presenting generalized spike and slow waves and atypical absences at the latest observations. Two patients (6 and 28) initially presenting with an MAE-like phenotype and irregular generalized spikes and slow waves, transitioned to showing only focal epileptiform abnormalities in the centro-parietotemporal regions at the time of the inclusion in this study (school age). In both cases, the epileptiform abnormalities were markedly enhanced by sleep, as it occurs in encephalopathy with status epilepticus during sleep (ESES). In 1 patient, the spikewave index during non-rapid eye movement (NREM) sleep was 82% (Figure 4 ) and in the other, the EEG was reported as "almost continuous epileptic activity" during NREM sleep. In neither patient was this EEG pattern associated with cognitive/behavioral deterioration as seen in ESES.
Brain magnetic resonance imaging (MRI) was unremarkable in the majority of SLC6A1 mutation carriers for whom data were available (14/19) . Five cases had nonspecific MRI abnormalities, such as mild vermian hypoplasia or enlarged frontal spaces. 
| DISCUSSION
In the present study, we describe the clinical features of 34 patients with pathogenic variants in SLC6A1 (24 probands, 6 family members, as well as 4 cases previously published 8, 9 ) and the EEG features of 28 of them.
The identified variants include several truncating variants supporting loss of function of GAT-1 as a disease mechanism, as reported previously. 6 Within this study, we found 4 recurring missense variants (Gly232Val, Ala288-Met, Val342Met, and Gly362Arg), suggesting possible mutational "hot spots" in SLC6A1.
In contrast to the previously published cases with SLC6A1 variants, this cohort displays a broader phenotypic spectrum sharing some common key features.
| Cognitive and behavioral deficits
The clinical hallmark of the SCL6A1 variant carriers is cognitive impairment. Almost all subjects (33/34) presented certain degrees of cognitive deficits at the time of observation, consisting of mild-to-moderate ID in 82% of the cases (28/ 34). Speech difficulties were a common feature, as reported previously, present in 17/34 of patients, whereas pure nonverbal deficits were uncommon. In half of the cases (17/34), we also observed behavioral problems, namely, attention deficit, hyperactivity, aggressive behavior, hand stereotypies, and autistic features in different combinations. This observation is supported by the data in the Scl6a1 mouse model. 13 Recently, a study found that selected SLC6A1 variants may correlate with a higher risk of Attention-deficit/hyperactivity disorder (ADHD) in humans.
14 Of interest, 3/34 SLC6A1 variant carriers never had epileptic seizures, but manifested only learnings disabilities or mild ID with or without autistic features, which represent a previously undescribed phenotype associated with SLC6A1. Two of these individuals had relatives, carrying the same variant, with an MAE phenotype, suggesting variable expressivity possibly due to either genetic or environmental modifying factors, and indicating that genotype-phenotype correlations are not straightforward. 
| Epilepsy
Thirty-one of 34 patients had epilepsy, with a mean age at onset of 3.7 years. The majority (24/30) of the patients displayed absences as the main seizure type, in agreement with studies in mice, that have shown an electroclinical phenotype consistent with atypical absence seizures. 4 We identified 16 subjects classified as MAE. Doose et al. stated that MAE usually begins in previously normally developing children. 15 However, he did not propose a "rigid"
syndrome, but rather a condition with unifying features plus a recognized phenotypic variability attributed to a multifactorial background. In our cohort, the most common phenotype associated with SLC6A1 could indeed be classified as MAE, associated in most of the patients with various degrees of ID before epilepsy onset, as also observed previously. 9 Five patients were diagnosed as having a variety of other generalized epilepsy syndromes, including phenotypes resembling CAE (Patient 25) and EOAE (Patient 1), in both cases associated with mild-to-moderate ID. The phenotypes of CAE and EOAE have previously been observed in SLC2A1, GABRB3, and CACNA1H, [16] [17] [18] but we now extend the genetic etiology of these 2 epilepsy phenotypes to include SLC6A1. Finally, in 4 patients, diagnosed as "unclassified generalized," the inconsistencies between the clinical features and the EEG findings did not allow a syndromic classification. Two patients presented with a phenotype resembling aBECTS, although with atypical electroclinical features (Patients 6 and 28), and 1 had temporal lobe epilepsy (Patient 24). This has not been described in any of the Slc6a1 animal models or human SLC6A1 variant carriers. 19 The subjects with aBECTS presented an extreme activation of the epileptiform abnormalities during NREM sleep resembling an ESES pattern. Surprisingly, both subjects developed aBECTS as an evolution of an MAE-like phenotype. A third subject presenting with aBECTS at epilepsy onset (Patient 12), evolved into a generalized epilepsy difficult to classify later, suggesting that the electroclinical features of SLC6A1-related epilepsy are variable and can change over time. Finally, 1 patient (25) was diagnosed with an epileptic encephalopathy of the LGS type. Data about cognition before epilepsy onset were available in 24/31 patients. Only 5 had normal cognitive development, whereas 64% of the subjects (16/24) presented mild-to-moderate ID. After epilepsy onset, cognition deteriorated in 44% of cases (11/24) and did not improve after seizure control was achieved. Therefore, the contribution of epilepsy to the development of the cognitive impairment in patients with a pathogenic SLC6A1 variant is uncertain.
| EEG data
Most patients exhibited a similar EEG pattern consisting of irregular, generalized 2.5-3.5 Hz spike/polyspikes-and-waves, providing a neurophysiological link to the animal studies. The clinical correlate of these EEG discharges could be an absence seizure, in most cases with atypical features, and with atonic and/or myoclonic components (16/28 cases). In our cohort, differences in the EEG pattern and in the associated clinical manifestations led to different phenotypical classification such as MAE, LGS, EOAE, or CAE. In 3 patients, the epileptiform abnormalities transitioned from generalized to strictly focal in the centro-parietotemporal regions (Patients 6 and 28) and vice versa (Patient 12) during the disease.
| Epilepsy treatment
The limited data thus far available suggest a good response to VPA, either as monotherapy or in combination with other antiepileptic drugs (AEDs). Ten of 15 patients treated with VPA became seizure-free, and the remaining 5 had a partial benefit. VPA is thought to have a positive effect on the GABA system (possibly increasing the GABA concentration in the human brain. 20 ), which could be part of the explanation for the favorable response to this drug.
| Neurological signs
Electroclinical studies in mice have suggested that the tonic inhibition in the brain also leads to motor disturbances, such as ataxia, which correlates well with the observation that the GABA transporters are highly present in the cerebellum as well as in cortical neurons. 1 We found that 29% (9/31) of the patients had mild ataxia or unsteady gait. A few patients displayed other cerebellar signs such as mild hypotonia, tremor, and fine-motor impairment, in accordance with the hypothesis of a slight perturbation of motor control in animal models. 4 Overall, we can conclude that humans carrying pathogenic SLC6A1 variants do not seem to display severe neurological symptoms. These data combined with those of Carvill et al. 9 suggest that typically SLC6A1-positive patients have mild-tomoderate ID, with language delay being one of the major features, preceding the onset of an epilepsy with an MAE phenotype. Therefore, in children with ID with or without behavioral disturbances, developing polymorphic seizure types, including absences, myoclonic and atonic seizures, and rare or no GTCS, screening for SLC6A1 should be undertaken. In addition, we describe cases never developing epilepsy. Because most patients described to date are children or young adults, longitudinal follow-up will be important to understand how seizures and cognition may change with age.
With this study, we define the phenotypic spectrum of clinical manifestations associated with SLC6A1 variants to include different forms of generalized epilepsies, but also a few cases of focal epilepsies as well as cases with ID without epilepsy. We confirm that the predominant epilepsy phenotype is MAE with preexisting mild-to-moderate ID with or without behavioral symptoms. Further studies are needed to confirm the phenotypic spectrum and to investigate the functional consequences of pathogenic variants in SLC6A1.
